Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6,545 JPY | -0.06% | +7.47% | -7.19% |
Apr. 24 | Biogen beats quarterly profit estimates, Alzheimer's drug sales jump | RE |
Apr. 23 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.97 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.19% | 11.92B | A- | ||
+29.68% | 699B | C+ | ||
+25.07% | 571B | B | ||
-4.35% | 364B | C+ | ||
+17.65% | 326B | B- | ||
+3.77% | 286B | C+ | ||
+14.68% | 236B | B+ | ||
+4.71% | 198B | B- | ||
-12.43% | 194B | A+ | ||
-3.79% | 154B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4523 Stock
- Ratings Eisai Co., Ltd.